Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. (28th October 2018)
- Record Type:
- Journal Article
- Title:
- Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. (28th October 2018)
- Main Title:
- Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib
- Authors:
- Dyczynski, Matheus
Yu, Yasmin
Otrocka, Magdalena
Parpal, Santiago
Braga, Tiago
Henley, Aine Brigette
Zazzi, Henric
Lerner, Mikael
Wennerberg, Krister
Viklund, Jenny
Martinsson, Jessica
Grandér, Dan
De Milito, Angelo
Pokrovskaja Tamm, Katja - Abstract:
- Abstract: Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance. In this study we systematically screened a library of 306 known anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7 and Vps34. These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies. For the pharmacological inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo . Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer. Highlights: High-Content screen identified 114 out of 306 anticancer drugs that induce autophagy. Kinase inhibitors Sunitinib and Erlotinib induced autophagy in breast cancer cells. We characterized SB02024,Abstract: Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance. In this study we systematically screened a library of 306 known anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7 and Vps34. These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies. For the pharmacological inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo . Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer. Highlights: High-Content screen identified 114 out of 306 anticancer drugs that induce autophagy. Kinase inhibitors Sunitinib and Erlotinib induced autophagy in breast cancer cells. We characterized SB02024, a novel highly potent and selective inhibitor of Vps34. SB02024 reduced xenograft growth of the two breast cancer cell lines in vivo . SB02024 increased kinase inhibitor-mediated cytotoxicity of breast cancer cells. … (more)
- Is Part Of:
- Cancer letters. Volume 435(2018)
- Journal:
- Cancer letters
- Issue:
- Volume 435(2018)
- Issue Display:
- Volume 435, Issue 2018 (2018)
- Year:
- 2018
- Volume:
- 435
- Issue:
- 2018
- Issue Sort Value:
- 2018-0435-2018-0000
- Page Start:
- 32
- Page End:
- 43
- Publication Date:
- 2018-10-28
- Subjects:
- Autophagy -- Combination therapy -- Erlotinib -- Vps34 -- High-content screening
AKT Protein kinase B -- ATG7 Autophagy-related protein 7 -- BafA1 Bafilomycin A1 -- Chk1 Checkpoint kinase 1 -- CQ Chloroquine -- FGFR Fibroblast growth factor receptor -- GFP Green fluorescent protein -- HCQ Hydroxychloroquine -- HDAC Histone deacetylase -- HER2 Human epidermal growth factor receptor 2 -- KU KU-0063794 -- LC3 Microtubule-associated proteins 1A/1B light chain 3 -- MCL-1 Induced myeloid leukemia cell differentiation protein 1 -- MCS Multicellular spheroids -- mTOR Mechanistic target of Rapamycin -- NCOA4 Nuclear receptor coactivator 4 -- p62 Sequestosome-1/p62 -- PI3K Phosphatidylinositol-3-kinase -- PI3P Phosphatidylinositol 3-phosphate -- PROPPIN β-propellers that bind polyphosphoinositides -- Vps34 Vacuolar protein sorting 34
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2018.07.028 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23166.xml